Tiblio
Sign Up

BFRIW

Biofrontera Inc. Warrants
NASDAQ

Key Statistics

Market Cap
—
P/E Ratio
—
EPS
$-1.30
Beta
0.82
52W High
$0.19
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
-25.70%
Forward P/E
—
PEG Ratio
—

About Biofrontera Inc. Warrants

Biofrontera Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative dermatological therapies, with a particular emphasis on skin cancer treatments. The company's flagship product, Ameluz, is a leading therapy for actinic keratosis, supported by a sophisticated photodynamic therapy system that significantly improves patient outcomes. With a robust pipeline aimed at expanding its product offerings and global market presence, Biofrontera is strategically positioned to capitalize on the increasing demand for effective skin cancer solutions and to forge partnerships that will enhance its competitive standing in the healthcare sector.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$43.20M
Gross Profit (TTM)$33.39M
EBITDA$-10.56M
Operating Margin-39.00%
Return on Equity-339.00%
Return on Assets-32.40%
Revenue/Share (TTM)$3.97
Book Value$0.51
Price-to-Book—
Price-to-Sales (TTM)—
EV/Revenue-
EV/EBITDA—
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)17.40%
Shares Outstanding0
Float$9.08M
% Insiders0.00%
% Institutions0.00%

Historical Volatility

HV 10-Day
212.33%
HV 20-Day
265.39%
HV 30-Day
259.77%
HV 60-Day
257.86%
HV Rank
—

Volatility is currently contracting

Latest News

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

GlobeNewsWire5/21/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BFRIW and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works
Data last updated: 7/29/2026